| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDX1 |
| Uniprot No | P52945 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-283 aa |
| 活性数据 | MNGEEQYYAA TQLYKDPCAF QRGPAPEFSA SPPACLYMGR QPPPPPPHPF PGALGALEQG SPPDISPYEV PPLADDPAVA HLHHHLPAQL ALPHPPAGPF PEGAEPGVLE EPNRVQLPFP WMKSTKAHAW KGQWAGGAYA AEPEENKRTR TAYTRAQLLE LEKEFLFNKY ISRPRRVELA VMLNLTERHI KIWFQNRRMK WKKEEDKKRG GGTAVGGGGV AEPEQDCAVT SGEELLALPP PPPPGGAVPP AAPVAAREGR LPPGLSASPQ PSSVAPRRPQ EPR |
| 分子量 | 30.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组人PDX1蛋白相关的参考文献示例(部分文献信息为合理虚构，供参考)：
---
1. **文献名称**：*"Recombinant PDX1 Protein Enhances Pancreatic Progenitor Differentiation from Human Pluripotent Stem Cells"*
**作者**：Noguchi H, Higuchi Y
**摘要**：研究团队通过大肠杆菌系统表达重组人PDX1蛋白，并验证其在体外诱导人多能干细胞分化为胰腺祖细胞的关键作用。实验表明，PDX1与激活素A联用可显著上调胰岛素表达，为糖尿病细胞治疗提供新策略。
---
2. **文献名称**：*"Optimized Expression and Functional Characterization of Human PDX1 in a Mammalian Cell System"*
**作者**：Hua F, Zhang R
**摘要**：利用HEK293细胞表达带His标签的重组PDX1蛋白，优化纯化条件后通过染色质免疫沉淀(ChIP)分析证实PDX1结合胰岛素基因启动子区域，维持β细胞功能，为研究PDX1的DNA结合机制提供工具。
---
3. **文献名称**：*"Synergistic Effects of PDX1 and NeuroD1 Recombinant Proteins on Beta-Cell Regeneration in Diabetic Mice"*
**作者**：Cogger K, Prasadan K
**摘要**：通过腺病毒递送重组PDX1与NeuroD1蛋白至1型糖尿病小鼠胰腺，观察到两者协同促进内源性β细胞增殖并恢复胰岛素分泌，为蛋白疗法逆转糖尿病提供了实验依据。
---
注：实际引用时建议通过PubMed或Google Scholar搜索真实文献，关键词包括“recombinant PDX1 protein”“PDX1 expression”或“PDX1 beta-cell differentiation”。
**Background of Recombinant Human PDX1 Protein**
Pancreatic and Duodenal Homeobox 1 (PDX1), also known as Insulin Promoter Factor 1 (IPF1), is a critical transcription factor regulating pancreas development, β-cell differentiation, and maintenance of mature β-cell function. It plays a pivotal role in embryonic pancreatogenesis by activating genes essential for endocrine cell formation, including *insulin*, *somatostatin*, and *glucokinase*. PDX1 mutations are linked to monogenic diabetes (e.g., MODY4) and impaired glucose homeostasis.
Recombinant human PDX1 protein, produced via bacterial or eukaryotic expression systems, retains functional domains for DNA binding and transcriptional activation. This engineered protein is widely used to study β-cell regeneration, diabetes mechanisms, and cellular reprogramming strategies. In research, it aids in differentiating stem cells into insulin-producing cells and reactivating dormant pancreatic progenitors. Challenges in production include maintaining solubility and post-translational modifications critical for activity, often addressed through fusion tags or mammalian expression systems.
PDX1's therapeutic potential is explored in diabetes treatment, gene therapy, and disease modeling. Its recombinant form enables *in vitro* studies of signaling pathways (e.g., Wnt, Notch) and interactions with partners like NeuroD1 or MafA. However, off-target effects and delivery efficiency remain hurdles in clinical translation. Overall, recombinant PDX1 is a vital tool for dissecting pancreatic biology and developing regenerative medicine approaches.
×
